Skip to main content

Curis, Inc. (CRIS)

NASDAQ: CRIS · Delayed Price · USD
7.99
+0.02 (0.25%)
After-hours:Sep 20, 2021 7:59 PM EDT
7.97
-0.51 (-6.01%)
At close: Sep 20, 4:00 PM
Market Cap747.43M
Revenue (ttm)10.24M
Net Income (ttm)-34.26M
Shares Out91.55M
EPS (ttm)-0.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,614,285
Open8.25
Previous Close8.48
Day's Range7.83 - 8.43
52-Week Range1.01 - 17.40
Beta2.93
AnalystsBuy
Price Target23.00 (+188.6%)
Est. Earnings DateNov 9, 2021

About CRIS

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid ...

IndustryBiotechnology
IPO DateAug 1, 2000
CEOJames Dentzer
Employees28
Stock ExchangeNASDAQ
Ticker SymbolCRIS
Full Company Profile

Financial Performance

In 2020, Curis, Inc.'s revenue was $10.84 million, an increase of 8.31% compared to the previous year's $10.00 million. Losses were -$29.91 million, -6.95% less than in 2019.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Curis, Inc. stock is "Buy." The 12-month stock price forecast is 23.00, which is an increase of 188.58% from the latest price.

Price Target
$23.00
(188.58% upside)
Analyst Consensus: Buy

News

Why Curis Stock Perked Up in August

The biotech's shares rode the wave of buyout speculation higher last month.

1 week ago - The Motley Fool

Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass., Sept. 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

2 weeks ago - PRNewsWire

Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of -9.09% and -1.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Recap: Curis Q2 Earnings

Shares of Curis (NASDAQ:CRIS) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 29.41% year over year to ($0.12), which missed the est...

1 month ago - Benzinga

Curis Reports Second Quarter 2021 Financial Results

LEXINGTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its f...

1 month ago - PRNewsWire

Will Curis (CRIS) Report Negative Q2 Earnings? What You Should Know

Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Curis to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 3, 2021

LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

1 month ago - PRNewsWire

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., July 7, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

2 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS

New York, New York--(Newsfile Corp. - June 26, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are advised t...

2 months ago - Newsfile Corp

Curis, Inc. Set to Join Russell 2000®, 3000® and Microcap® Indexes

LEXINGTON, Mass., June 25, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

2 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS

NEW YORK, June 22, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are advised to contact Rober...

2 months ago - PRNewsWire

Why Curis Fell Off a Cliff on Friday

The company will bring a lower dose of an important pipeline drug into a phase 2 clinical trial.

3 months ago - The Motley Fool

Curis Shares Drop After Updated CA-4948 Data From Mid-Stage Blood Cancer Trial

Curis Inc (NASDAQ: CRIS) has announced updated data from its ongoing Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Key findings w...

3 months ago - Benzinga

Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed o...

LEXINGTON, Mass., June 11, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced upd...

3 months ago - PRNewsWire

Curis to Host Virtual Event to Discuss Updated Clinical Data for CA-4948 in AML/MDS Presented at EHA

LEXINGTON, Mass., June 4, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

3 months ago - PRNewsWire

Curis, Inc. Announces 2021 Virtual Symposium: "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond"

LEXINGTON, Mass., June 1, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the ...

3 months ago - PRNewsWire

Curis to Present at Jefferies Virtual Healthcare Conference

LEXINGTON, Mass., May 25, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

3 months ago - PRNewsWire

New Strong Sell Stocks for May 20th

AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2021

Other symbols:AXDXFSTRGOPRLB
4 months ago - Zacks Investment Research

Why Curis Stock Crashed on Thursday

The swoon came shortly after some very good news for the company.

4 months ago - The Motley Fool

Curis Shares Drop On Safety Issues From Leukemia Study With CA-4948; Q1 Earnings Missing Estimates

Curis Inc (NASDAQ: CRIS) stock gained momentum yesterday in reaction to updated data from its Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndro...

4 months ago - Benzinga

Curis Reports First Quarter 2021 Financial Results

LEXINGTON, Mass., May 12, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its f...

4 months ago - PRNewsWire

Why Curis (CRIS) Shares Are Surging Today?

Curis Inc (NASDAQ: CRIS) shares are surging in reaction to updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk mye...

4 months ago - Benzinga

Curis Reports Updated Data in Two Abstracts for CA-4948 Accepted for Presentation at the European Hematology Associat...

LEXINGTON, Mass., May 12, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

4 months ago - PRNewsWire

Do Options Traders Know Something About Curis (CRIS) Stock We Don't?

Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021

LEXINGTON, Mass., May 5, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that ...

4 months ago - PRNewsWire